Eli Lilly (LLY) on Tuesday launched higher doses of Zepbound, or tirzepatide, in single-dose vials and reduced the prices of two smaller doses of the weight-loss drug for self-pay patients.
This, along with their established partnerships with Ro and Amazon pharmacies, should broaden access to the drug, boosting volumes and sales.